Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, shared on X: about a recent paper by David H. Ilson published on JCO:
“Thoroughly enjoyed reading this editorial by Dr. Ilson in JCO
KEYNOTE-585: Pembro + cisplatin/5FU ↑ pCR but EFS/OS.
MATTERHORN: Durva + FLOT ↑ pCR and EFS, setting a new periop standard in resectable gastric/GEJ cancer.
Comparable outcomes for FLOT plus pembrolizumab from KEYNOTE-585 and FLOT plus durvalumab from MATTERHORN
Even as a ‘negative’ trial, KEYNOTE-585 reinforces the MATTERHORN results; IO has a role, but the chemo backbone matters.
Big question- does PD-L1 CPS matter?”
Title: KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
Nina Niu Sanford, Associate Professor at UT Southwestern Medical Center, shared Udhayvir Grewal’s on X:
“It never made sense to me for a Ph3 RCT to have 4 primary endpts: pCR, EFS, OS, safety.
Wo multiplicity strategy (for endpts/looks), KN585 likely pos.
IMO also illustrates challenges in evaluating clinical v stat significance, and again questions why we hang everything on p=0.05.
Btw this was nicely discussed in post by Amol Akhade”
David Sher, Vice Chair of Clinical Operations and Quality, Medical Director of Radiation Oncology, Chief of Head and Neck Radiation Oncology Service at UTSW Medical Center, commented on this post:
“As if on cue.
Nina Niu Sanford, shared his comment, adding:
“Wow, yes – on cue!
Another great Stats for the People in IJROBP – The Red Journal nicely explaining many of the issues on this thread re: p-values.
Agree with conclusions, and dos/don’ts here.”
More posts featuring Udhayvir Grewal.